Dutch gene therapy firm UniQure threw its hat into the RNAi ring this week, announcing that it has picked up non-exclusive access to Benitec Biopharma's proprietary expressed RNAi technology for use with its nascent Huntington's disease program.

In doing so, the company hopes to apply its core adeno-associated virus technology with the gene-silencing technology, potentially opening the door to other RNAi programs, Hans Preusting, UniQure senior vice president of business development, told Gene Silencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.